GlassScriptPhysician profile
Daniel J Kleinman
NPI 1255309969
$745.20
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $85.09.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $214.83 | 2019-2020 | |
| Amgen INC. | $100.26 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.86 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $95.11 | 2019 | |
| Boston Scientific Corporation | $52.85 | 2019-2020 | |
| Amarin Pharma, INC. | $41.87 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $34.97 | 2019 | |
| W. L. Gore & Associates, INC. | $31.99 | 2020 | |
| Lundbeck LLC | $24.92 | 2019 | |
| Pfizer INC. | $21.95 | 2019 | |
| Chiesi USA, INC. | $14.69 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.90 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kleinman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.